Advanced search
Publication Cover
Journal of Asthma Volume 61, 2024 - Issue 7
Submit an article Journal homepage
162
Views
0
CrossRef citations to date
0
Altmetric
Case Report

Global influence of dupilumab on Quality of Life in a severe asthma patient with T2 multimorbidities: a case report on atopic dermatitis, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis

Monica Colque-Bayonaa Department of Allergy, La Paz University Hospital, Madrid, SpainCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1534-5573View further author information
, MDORCID Icon,
Natalia Hernández-Canob Department of Dermatology, La Paz University Hospital, Madrid, SpainView further author information
, MD,
Margarita Tomás-Péreza Department of Allergy, La Paz University Hospital, Madrid, Spain;c La Paz Institute for Health Research (IdiPAZ), Madrid, SpainView further author information
, MD,
Teresa Caballeroa Department of Allergy, La Paz University Hospital, Madrid, Spain;c La Paz Institute for Health Research (IdiPAZ), Madrid, Spain;d Biomedical Research Network on Rare Diseases (CIBERER U754), Madrid, SpainView further author information
, MD, PhD,
Santiago Quircea Department of Allergy, La Paz University Hospital, Madrid, Spain;c La Paz Institute for Health Research (IdiPAZ), Madrid, Spain;e CIBER of Respiratory Diseases (CIBERES), Madrid, SpainView further author information
, MD, PhD &
Javier Domínguez-Ortegaa Department of Allergy, La Paz University Hospital, Madrid, Spain;c La Paz Institute for Health Research (IdiPAZ), Madrid, Spain;e CIBER of Respiratory Diseases (CIBERES), Madrid, SpainView further author information
, MD, PhD
Pages 762-765 | Received 10 Oct 2023, Accepted 26 Dec 2023, Published online: 04 Jan 2024

References

  • Shankar A, McAlees JW, Lewkowich IP. Modulation of IL-4/IL-13 cytokine signaling in the context of allergic disease. J Allergy Clin Immunol. 2022;150(2):266–276. Cited in: PMID: 35934680. doi:10.1016/j.jaci.2022.06.012.
  • Papi A, Corren J, Castro M, Domingo C, Rogers L, Chapman KR, Jackson DJ, Daizadeh N, Pandit-Abid N, Gall R, et al. Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate-to-severe type 2 asthma. Allergy. 2023;78(1):233–243. Cited in: PMID: 35899469. doi:10.1111/all.15456.
  • Agency EEM. 2018. [cited 2023 May 27]. Dupixent. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent
  • Maspero J, Adir Y, Al-Ahmad M, Celis-Preciado CA, Colodenco FD, Giavina-Bianchi P, Lababidi H, Ledanois O, Mahoub B, Perng D-W, et al. Type 2 inflammation in asthma and other airway diseases. ERJ Open Res. 2022;8(3):00576-2021. doi:10.1183/23120541.00576-2021.
  • Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425–437. Cited in: PMID: 28277826. doi:10.1080/1744666X.2017.1298443.
  • Muñoz-Bellido F, Moreno E, Dávila I. Dupilumab: a review of present indications and off-label uses. J Investig Allergol Clin Immunol. 2022;32(2):97–115. Cited in: PMID: 33661102. doi:10.18176/jiaci.0682.
  • Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2022. Available from: www.ginasthma.org.
  • Boguniewicz M, Beck LA, Sher L, Guttman-Yassky E, Thaçi D, Blauvelt A, Worm M, Corren J, Soong W, Lio P, et al. Dupilumab improves asthma and sinonasal outcomes in adults with moderate to severe atopic dermatitis. J Allergy Clin Immunol Pract. 2021;9(3):1212–1223.e6. Cited in: PMID: 33453450. doi:10.1016/j.jaip.2020.12.059.
  • Pose K, Laorden D, Hernández N, Villamañán E, Quirce S, Domínguez-Ortega J. Concomitant Efficacy of Dupilumab for severe atopic dermatitis and comorbid asthma in real-life conditions. J Investig Allergol Clin Immunol. 2023;33(3):217–219. Cited in: PMID: 37318773. doi:10.18176/jiaci.0837.
  • Pelaia C, Lombardo N, Busceti MT, Piazzetta G, Crimi C, Calabrese C, Vatrella A, Pelaia G. Short-term evaluation of dupilumab effects in patients with severe asthma and nasal polyposis. J Asthma Allergy. 2021;14:1165–1172. Cited in: PMID: 34594115 doi:10.2147/JAA.S328988.
  • Spergel BL, Ruffner MA, Godwin BC, Liacouras CA, Cianferoni A, Gober L, Hill DA, Brown-Whitehorn TF, Chaiboonma K, Aceves SA, et al. Improvement in eosinophilic esophagitis when using dupilumab for other indications or compassionate use. Ann Allergy Asthma Immunol. 2022;128(5):589–593. Cited in: PMID: 35085819. doi:10.1016/j.anai.2022.01.019.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.